Alpha-1-antitrypsin modified process - Grifols

Drug Profile

Alpha-1-antitrypsin modified process - Grifols

Alternative Names: Alpha-1 MP - Grifols; Alpha-1 proteinase-inhibitor-modified process - Grifols; Alpha-1-antitrypsin IV - Grifols; Alpha-1-protease-inhibitor-modified process - Grifols; Alpha-antitrypsin modified process - Grifols; Alpha1-PI; Prolastin C; Prolastin-C; TAL 6004

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Bayer
  • Developer Grifols
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II Chronic fatigue syndrome; Type 1 diabetes mellitus

Most Recent Events

  • 01 Nov 2016 Grifols Therapeutics initiates enrolment in a phase I/II trial for Alpha 1-antitrypsin deficiency in Japan (JapicCTI-163194)
  • 29 Mar 2016 Grifols Therapeutics initiates the extension phase III SPARTA-OLE trial for Alpha 1-antitrypsin deficiency in Denmark (IV) (EudraCT2015-004110-23)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top